■ Decision on Acquisition of Shares or Investment Securities of Other Corporation

<table>
<tr><td colspan="2" rowspan="4">1. Details of Issuing Company</td><td colspan="2">Name of Company</td><td colspan="2">Volpara Health Technologies Limited</td></tr>
<tr><td>Nationality</td><td>New Zealand</td><td>Representative</td><td>Teri Thomas (CEO)</td></tr>
<tr><td>Capital Stock (KRW)</td><td>149,589,039,840</td><td>Relationship to Company</td><td>-</td></tr>
<tr><td>Total Number of Issued Shares</td><td>254,374,308</td><td>Main Business</td><td>AI-powered software for screening and early detection of breast cancer</td></tr>
<tr><td colspan="2">- Applicability of attaining new shares through Third Party Allotment within the last 6 months</td><td colspan="4">N/A</td></tr>
<tr><td rowspan="6">2. Details of Acquisition</td><td>Number of Shares to Be Acquired</td><td colspan="4">254,374,308</td></tr>
<tr><td>Acquisition Price (KRW)(A)</td><td colspan="4">252,541,541,111</td></tr>
<tr><td>Total Assets (KRW)(B)</td><td colspan="4">97,153,074,707</td></tr>
<tr><td>Ratio to Total Assets (%)(A/B)</td><td colspan="4">259.94</td></tr>
<tr><td>Equity Capital (KRW)(C)</td><td colspan="4">68,909,657,614</td></tr>
<tr><td>Ratio to Equity Capital (%)(A/C)</td><td colspan="4">366.48</td></tr>
<tr><td colspan="2" rowspan="2">3. Number of Shares Held and Ownership Ratio after Acquisition</td><td>Number of Shares Held</td><td colspan="3">254,374,308</td></tr>
<tr><td>Ownership (%)</td><td colspan="3">100</td></tr>
<tr><td colspan="2">4. Purpose of Acquisition</td><td colspan="4">Diversification of business and strengthening global business competitiveness</td></tr>
<tr><td colspan="2">5. Expected Date of Acquisition</td><td colspan="4">2024.04.30</td></tr>
<tr><td rowspan="5">6. Counterparty</td><td>Name</td><td colspan="4">Volpara Health Technologies Limited</td></tr>
<tr><td>Capital Stock (KRW)</td><td colspan="4">149,589,039,840</td></tr>
<tr><td>Main Business</td><td colspan="4">AI-powered software for screening and early detection of breast cancer</td></tr>
<tr><td>HQ Address</td><td colspan="4">Level 14, 40 Mercer Street, Wellington Central, Wellington 6011, New Zealand</td></tr>
<tr><td>Relationship to Company</td><td colspan="4">-</td></tr>
<tr><td colspan="2">7. Acquisition Method</td><td colspan="4">1. Payment Method: Cash
2. Expected Payment Date: Full payment on the date of acquisition (AUD 292,530,454.20)
3. Financing Method: Acquisition financing and capital increase</td></tr>
<tr><td rowspan="2">8. Matters regarding External Evaluation</td><td>Applicability of External Evaluation</td><td colspan="4">Yes</td></tr>
<tr><td>Purpose and Reason</td><td colspan="4">4. Purpose: Intended for use as attached documents submitted to the Financial Services Commission in accordance with Article 161 of the Financial Investment Services and Capital Markets Act and Article 171 of its enforcement decree</td></tr>
</table>

		2. Reasons: Prepared for reference in the internal decision-making process of the company for the share acquisition transaction, and for use in the preparation and attachment of major reports submitted by the company in accordance with the provisions of the Financial Investment Services and Capital Markets Act.
	Name of the External Evaluation Agency	KPMG Samjong Accounting Corp.
	External evaluation period	2023.11.28~2023.12.12
	External evaluation opinion	Received appropriate opinion
9. Date of Board of Directors' Resolution (Decision Date)		2023.12.14
- Attendance of Outside Directors	Present (No.)	1
	Absent (No.)	-
- Attendance of Auditors (members of Audit Committee)		Yes
10. Applicability of Criteria for backdoor listing		No
- Capital Increase Plan (allotment to the third parties) within 6 months		No
11. Satisfaction for issuer (other corporation) to backdoor listing requisite		No
12. Applicability of Monopoly Regulation and Fair-Trade Act		No
13. If entered into an agreement for Put Option, Call Option, Put Back Option, etc.		No
- Details of agreements		-

14. The Future Plans for Company Restructuring

As of the reporting date, Lunit Inc.(the "Lunit") has not made any specific plans regarding future restructuring of the company.

15. Other references concerning investment decisions

1) Volpara Health Technologies Limited(the "Volpara") is established in New Zealand and is currently listed on the Australian Securities Exchange (ASX).

2) The 'Capital Stock' in the above '1. Issuing Company' is NZD 183,266 thousand, based on the consolidated financial statements for the recent fiscal year ending on March 31, 2023. This amount has been converted to Korean Won using the exchange rate of 816.24 KRW/NZD as of March 31, 2023, based on the Seoul Money Brokerage.

3) The 'Number of Shares to Be Acquired' in the above '2. Details of Acquisition' refers to the number of shares as of the contract date, and the final number of acquired shares may change if employee options are exercised before the completion date of the transaction.

4) The 'Acquisition Price' in the above '2. Details of Acquisition' is AUD 292,530,454.20, converted to Korean Won using the exchange rate as of the day before the Board of Directors meeting based on the Seoul Money Brokerage (KRW/AUD= 863.30). If employee options are exercised before the completion date of the transaction, the final acquisition price may change.

5) The 'Total Assets' and 'Equity Capital' in the above '2. Details of Acquisition' are based on Lunit's consolidated financial statements as of the end of 2022.

6) The '5. Expected Date of Acquisition' is the anticipated date for concluding the contract, subject to the fulfillment of all condition precedent outlined in the Scheme Implementation Agreement. This date is subject to change in the future.

※ Key Condition Precedent

① Obtain approval from New Zealand Overseas Investment office

② Obtain approval from the shareholders of Volpara

③ Obtain approval from the High Court of New Zealand

7) Volpara will be delisted from the ASX upon the completion of the acquisition process.

8) Lunit plans to pay the share acquisition amount through acquisition financing and capital increase. Details of this will be provided once they are determined.

9) In the event of any confirmation or changes related to this disclosure, a re-disclosure will be announced.

10) For further details, please refer to the attached 'External Evaluation Report.'

[Summary of Financial Statement of Volpara]

(Currency: KRW in million)

Type	Total Assets	Total Liabilities	Total Equity	Capital Stock	Sales	Net Income	External Auditor's Opinion	External Auditor
This Year	64,658	22,825	41,833	149,589	28,577	-8,000	Unqualified	PWC
Last Year	68,399	19,507	48,892	153,290	22,055	-13,886	Unqualified	PWC
The Year before Last	74,905	17,272	57,633	143,041	15,634	-13,845	Unqualified	PWC

*1) The above is based on consolidated financial statements.
*2) Volpara ends its fiscal year as of March 31 each year. The amounts are converted to Korean Won using the exchange rate based on the Seoul Money Brokerage as of the end of that period.

[Applied Exchange Rate]

Type	March 31, 2021	March 31, 2022	March 31, 2023
KRW/NZD	791.69	844.59	816.24

[Information of Volpara]

1. Information

- General Information			
Name	Nationality	Address (City)	
Volpara Health Technologies Limited	New Zealand	Wellington 6011, New Zealand	
Occupation (Business Details)		AI-powered software for screening and early detection of breast cancer	
- Details of the largest shareholder and CEO (if the other party is a corporation)			
Type	Name	Number of Shares Held	Ownership (%)
Largest Shareholder	Harbour Asset Management Limited	38,705,649	15.22
CEO	Teri Thomas	332,564	0.13

(Currency: KRW in million)

Fiscal Year	2023	Fiscal Year End	March
Total Assets	64,658	Capital Stock	149,589
Total Liabilities	22,825	Sales	28,577
Total Equity	41,833	Net Income	-8,000
External Auditor	PWC	Applicability of Temporary Closure	No
External Auditor's Opinion	Unqualified	Applicability of Shut Down	No

2. Relationship with Lunit, its largest shareholder, and executives.

- Relationship between Lunit and Volpara		-
- Relationship between the Largest shareholder or executives Directors of Lunit and Volpara	Name	Relationship to Volpara
-	-	-

3. Transaction Details for the last 3years (except for routine transaction)

Type	Transaction Details
This Year	-
Last Year	-
The Year before Last	-